STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
B
Withdrawn
- COVID-19
- BRII-196 and BRII-198
- Placebo
- Hong Kong, ChinaInvestigative Site 1
2022-03-01
Mar 1, 2022B
Completed
- COVID-19
- BRII-196 and BRII-198
- Placebo
- Beijing, Beijing, ChinaInvestigative Site
2022-03-01
Mar 1, 2022B
Completed
- COVID-19
- BRII-196 and BRII-198
- Placebo
- Beijing, Beijing, China
- +5 more
2022-03-01
Mar 1, 2022N
Completed
- HIV Infections
- VRC01
- +2 more
- Los Angeles, California
- +13 more
2022-03-24
Mar 24, 2022L
Terminated
- Ovarian Cancer
- Monoclonal antibody hu3S193
- New York, New YorkMemorial Sloan-Kettering Cancer Center
2021-07-20
Jul 20, 2021F
M
Completed
- Neuroblastoma
- beta-glucan
- +3 more
- New York, New YorkMemorial Sloan Kettering Cancer Center
2022-03-04
Mar 4, 2022G
Active, not recruiting
- Metastatic Colon Cancer
- Chemotherapy
- Chemotherapy plus monoclonal antibody
- Alcoy, Alicante, Spain
- +47 more
2022-03-15
Mar 15, 2022M
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +10 more
- Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-03-30
Mar 30, 2022M
Active, not recruiting
- Brain and Central Nervous System Tumors
- +9 more
- DNA analysis
- +4 more
- New York, New YorkMemorial Sloan Kettering Cancer Center
2021-10-28
Oct 28, 2021L
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer - 2006
Completed
- Ovarian Cancer
- 90Y-hu3S193
- 111In-hu3S193
- New York, New YorkMemorial Sloan-Kettering Cancer Center
2021-11-23
Nov 23, 2021E
Active, not recruiting
- Colon Carcinoma Metastatic in the Liver
- +13 more
- Anti-SEMA4D Monoclonal Antibody VX15/2503
- +3 more
- Atlanta, Georgia
- +3 more
2021-12-15
Dec 15, 2021Z
Not yet recruiting
- Hematological Malignancies
- NK cells/Combined Monoclonal Antibodies
- Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
2020-12-08
Dec 8, 2020L
Terminated
- Colorectal Cancer
- monoclonal antibody hu3S193
- New York, New YorkMemorial Sloan-Kettering Cancer Center
2021-07-15
Jul 15, 2021M
Recruiting
- CD30-Positive Neoplastic Cells Present
- Malignant Mesothelioma
- Brentuximab Vedotin
- Laboratory Biomarker Analysis
- Houston, TexasM D Anderson Cancer Center
2022-01-03
Jan 3, 2022M
Recruiting
- Adult Acute Lymphoblastic Leukemia in Complete Remission
- +3 more
- Blinatumomab
- Laboratory Biomarker Analysis
- Houston, TexasM D Anderson Cancer Center
2021-09-22
Sep 22, 2021N
Completed
- HIV Infections
- F105 Monoclonal Antibody (Human)
- Boston, MassachusettsBeth Israel Deaconess Med. Ctr., ACTG CRS
2021-10-28
Oct 28, 2021W
Active, not recruiting
- Human Papillomavirus Infection
- +11 more
- Durvalumab
- +2 more
- Winston-Salem, North CarolinaComprehensive Cancer Center of Wake Forest University
2021-12-17
Dec 17, 2021M
Completed
- Neuroblastoma
- anti-GD2 murine IgG3 monoclonal antibody 3F8
- New York, New YorkMemorial Sloan-Kettering Cancer Center
2021-01-26
Jan 26, 2021J
Terminated
- Metastatic Melanoma
- +5 more
- Anti-SEMA4D Monoclonal Antibody VX15/2503
- +4 more
- Los Angeles, California
- +1 more
2021-04-01
Apr 1, 2021L
Completed
- Lung Cancer
- monoclonal antibody hu3S193
- New York, New YorkMemorial Sloan-Kettering Cancer Center
2022-02-07
Feb 7, 2022Y
Active, not recruiting
- Brain and Central Nervous System Tumors
- +2 more
- Iodine I 131 MOAB 8H9
- New York, New YorkMemorial Sloan Kettering Cancer Center
2022-02-07
Feb 7, 2022F
Terminated
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +32 more
- indium In 111 anti-CD45 monoclonal antibody BC8
- +2 more
- Seattle, WashingtonFred Hutchinson Cancer Research Center/University of Washington
2021-03-07
Mar 7, 2021B
Enrolling by invitation
- PTLD
- +2 more
- low-dose CD20 monoclonal antibody injection
- Beijing, Beijing, ChinaBeijing Friendship Hospital
2022-02-24
Feb 24, 2022U
Recruiting
- Non-Hodgkin Lymphoma
- +7 more
- Mosunetuzumab
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-28
Mar 28, 2022